FDA Weighs Patients' Risk Tolerance in Approving Obesity Device
This article was originally published in The Gray Sheet
The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.
You may also be interested in...
Patients Want Industry To Minimize Burdens, Augment Comforts Of Device Trial Participation
Patients and patient advocacy groups at the US FDA's inaugural Patient Engagement Advisory Committee meeting said they need sponsors to minimize the burdens and augment the comforts of trial participation, and get reports on outcomes along the way. Meanwhile, industry groups worried about revealing too much confidential business information, and biasing trial outcomes.
Final Guidance Encourages Use Of Patient Preference In Device Applications
US FDA released a final guidance aimed at helping sponsors and other stakeholders interested in using patient-preference information to make their case for a device application. The agency has decided to keep its labeling recommendation in the final guidance despite industry objections.
Assistive, Neurostim Devices Get 'Patient Preference' Attention From US FDA
The agency's patient-preference initiative is expanding with a new workshop that will unite FDA lab staff and patients to discuss patient perspectives on assistive and neurological stimulation devices.